Incidence of Multiple Sclerosis in the General Population in the Netherlands, 1996–2008
Background: We estimated the multiple sclerosis (MS) incidence in the Netherlands for better active monitoring of potential vaccine safety signals. Methods: A retrospective cohort study (1996–2008) was conducted using a population-based general practice research database containing electronic medica...
Gespeichert in:
| Veröffentlicht in: | Neuroepidemiology 2012-09, Vol.39 (2), p.96-102 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 102 |
|---|---|
| container_issue | 2 |
| container_start_page | 96 |
| container_title | Neuroepidemiology |
| container_volume | 39 |
| creator | Kramer, M.A. van der Maas, N.A.T. van Soest, E.M. Kemmeren, J.M. de Melker, H.E. Sturkenboom, M.C.J.M. |
| description | Background: We estimated the multiple sclerosis (MS) incidence in the Netherlands for better active monitoring of potential vaccine safety signals. Methods: A retrospective cohort study (1996–2008) was conducted using a population-based general practice research database containing electronic medical records. Additional information was collected to validate incident probable cases. Results: In the source population (648,656 persons), 146 incident probable MS cases were identified. Overall incidence rate was 6.3/100,000 person years (py; 95% CI, 5.2–7.2). In the subgroup in which MS could be fully validated, the incidence increased from 4/100,000 py (95% CI, 3–5) in 1996–2004 to 9/100,000 py in 2007/8 (95% CI, 6–16). This increase was highest among women, but not statistically significantly different by gender. The median lag time between first recorded symptoms and MS diagnosis decreased from 32 months (2005). Conclusions: MS is rare in the Netherlands. In recent years, there was a slight increase in the incidence especially among women during the fertile age. This increase coincided with a decrease in lag time between symptoms and diagnosis, both for men and women. This trend should be taken into account in the interpretation of MS cases occurring in a population where new vaccinations will be introduced shortly. |
| doi_str_mv | 10.1159/000338678 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_karge</sourceid><recordid>TN_cdi_karger_primary_338678</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1093447730</sourcerecordid><originalsourceid>FETCH-LOGICAL-c367t-3125a7d951a28f7bed7cb025b98c0a48787573e1ff9b2828756bb6304a0bf46b3</originalsourceid><addsrcrecordid>eNqN0b1OwzAQB3ALgWgpDOwIRWIBicDZTmJ7RBWUSuVDAgamyE4ukJImxU4GNt6BN-RJMOrHwMRiy_LPf53vCNmncEZprM4BgHOZCLlB-jRiPAQGcpP0gcU0jHkMPbLj3BTAY6m2SY8xSSOqoj55HtdZmWOdYdAUwU1XteW8wuAhq9A2rnRBWQftKwYjrNHqKrhv5l2l27KpVze36Fdb6Tp3pwFVKvn-_GIAcpdsFbpyuLfcB-Tp6vJxeB1O7kbj4cUkzHgi2pBTFmuRq5hqJgthMBeZ8YUbJTPQkRRSxIIjLQplmGT-lBiTcIg0mCJKDB-Q40Xu3DbvHbo2nZUuw8pXhE3nUgqKR5EQHP5BuWLApaCeHv2h06aztf9ISpnvtC8FmFcnC5X5ZjmLRTq35UzbDx-V_o4mXY_G28NlYmdmmK_lahYeHCzAm7YvaNdg-f4HkCWOoA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1267828202</pqid></control><display><type>article</type><title>Incidence of Multiple Sclerosis in the General Population in the Netherlands, 1996–2008</title><source>MEDLINE</source><source>Karger Journals</source><source>Alma/SFX Local Collection</source><creator>Kramer, M.A. ; van der Maas, N.A.T. ; van Soest, E.M. ; Kemmeren, J.M. ; de Melker, H.E. ; Sturkenboom, M.C.J.M.</creator><creatorcontrib>Kramer, M.A. ; van der Maas, N.A.T. ; van Soest, E.M. ; Kemmeren, J.M. ; de Melker, H.E. ; Sturkenboom, M.C.J.M.</creatorcontrib><description>Background: We estimated the multiple sclerosis (MS) incidence in the Netherlands for better active monitoring of potential vaccine safety signals. Methods: A retrospective cohort study (1996–2008) was conducted using a population-based general practice research database containing electronic medical records. Additional information was collected to validate incident probable cases. Results: In the source population (648,656 persons), 146 incident probable MS cases were identified. Overall incidence rate was 6.3/100,000 person years (py; 95% CI, 5.2–7.2). In the subgroup in which MS could be fully validated, the incidence increased from 4/100,000 py (95% CI, 3–5) in 1996–2004 to 9/100,000 py in 2007/8 (95% CI, 6–16). This increase was highest among women, but not statistically significantly different by gender. The median lag time between first recorded symptoms and MS diagnosis decreased from 32 months (<1998) to 2 months (>2005). Conclusions: MS is rare in the Netherlands. In recent years, there was a slight increase in the incidence especially among women during the fertile age. This increase coincided with a decrease in lag time between symptoms and diagnosis, both for men and women. This trend should be taken into account in the interpretation of MS cases occurring in a population where new vaccinations will be introduced shortly.</description><identifier>ISSN: 0251-5350</identifier><identifier>EISSN: 1423-0208</identifier><identifier>DOI: 10.1159/000338678</identifier><identifier>PMID: 22814194</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Adolescent ; Adult ; Age ; Age Distribution ; Aged ; Cohort Studies ; Databases, Factual ; electronic medical records ; Female ; Humans ; Incidence ; Male ; Middle Aged ; Multiple sclerosis ; Multiple Sclerosis - epidemiology ; Netherlands - epidemiology ; Original Paper ; Retrospective Studies ; Sex Distribution ; Vaccination ; Vaccines</subject><ispartof>Neuroepidemiology, 2012-09, Vol.39 (2), p.96-102</ispartof><rights>2012 S. Karger AG, Basel</rights><rights>Copyright © 2012 S. Karger AG, Basel.</rights><rights>Copyright (c) 2012 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c367t-3125a7d951a28f7bed7cb025b98c0a48787573e1ff9b2828756bb6304a0bf46b3</citedby><cites>FETCH-LOGICAL-c367t-3125a7d951a28f7bed7cb025b98c0a48787573e1ff9b2828756bb6304a0bf46b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,2422,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22814194$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kramer, M.A.</creatorcontrib><creatorcontrib>van der Maas, N.A.T.</creatorcontrib><creatorcontrib>van Soest, E.M.</creatorcontrib><creatorcontrib>Kemmeren, J.M.</creatorcontrib><creatorcontrib>de Melker, H.E.</creatorcontrib><creatorcontrib>Sturkenboom, M.C.J.M.</creatorcontrib><title>Incidence of Multiple Sclerosis in the General Population in the Netherlands, 1996–2008</title><title>Neuroepidemiology</title><addtitle>Neuroepidemiology</addtitle><description>Background: We estimated the multiple sclerosis (MS) incidence in the Netherlands for better active monitoring of potential vaccine safety signals. Methods: A retrospective cohort study (1996–2008) was conducted using a population-based general practice research database containing electronic medical records. Additional information was collected to validate incident probable cases. Results: In the source population (648,656 persons), 146 incident probable MS cases were identified. Overall incidence rate was 6.3/100,000 person years (py; 95% CI, 5.2–7.2). In the subgroup in which MS could be fully validated, the incidence increased from 4/100,000 py (95% CI, 3–5) in 1996–2004 to 9/100,000 py in 2007/8 (95% CI, 6–16). This increase was highest among women, but not statistically significantly different by gender. The median lag time between first recorded symptoms and MS diagnosis decreased from 32 months (<1998) to 2 months (>2005). Conclusions: MS is rare in the Netherlands. In recent years, there was a slight increase in the incidence especially among women during the fertile age. This increase coincided with a decrease in lag time between symptoms and diagnosis, both for men and women. This trend should be taken into account in the interpretation of MS cases occurring in a population where new vaccinations will be introduced shortly.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age</subject><subject>Age Distribution</subject><subject>Aged</subject><subject>Cohort Studies</subject><subject>Databases, Factual</subject><subject>electronic medical records</subject><subject>Female</subject><subject>Humans</subject><subject>Incidence</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis - epidemiology</subject><subject>Netherlands - epidemiology</subject><subject>Original Paper</subject><subject>Retrospective Studies</subject><subject>Sex Distribution</subject><subject>Vaccination</subject><subject>Vaccines</subject><issn>0251-5350</issn><issn>1423-0208</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqN0b1OwzAQB3ALgWgpDOwIRWIBicDZTmJ7RBWUSuVDAgamyE4ukJImxU4GNt6BN-RJMOrHwMRiy_LPf53vCNmncEZprM4BgHOZCLlB-jRiPAQGcpP0gcU0jHkMPbLj3BTAY6m2SY8xSSOqoj55HtdZmWOdYdAUwU1XteW8wuAhq9A2rnRBWQftKwYjrNHqKrhv5l2l27KpVze36Fdb6Tp3pwFVKvn-_GIAcpdsFbpyuLfcB-Tp6vJxeB1O7kbj4cUkzHgi2pBTFmuRq5hqJgthMBeZ8YUbJTPQkRRSxIIjLQplmGT-lBiTcIg0mCJKDB-Q40Xu3DbvHbo2nZUuw8pXhE3nUgqKR5EQHP5BuWLApaCeHv2h06aztf9ISpnvtC8FmFcnC5X5ZjmLRTq35UzbDx-V_o4mXY_G28NlYmdmmK_lahYeHCzAm7YvaNdg-f4HkCWOoA</recordid><startdate>201209</startdate><enddate>201209</enddate><creator>Kramer, M.A.</creator><creator>van der Maas, N.A.T.</creator><creator>van Soest, E.M.</creator><creator>Kemmeren, J.M.</creator><creator>de Melker, H.E.</creator><creator>Sturkenboom, M.C.J.M.</creator><general>S. Karger AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>201209</creationdate><title>Incidence of Multiple Sclerosis in the General Population in the Netherlands, 1996–2008</title><author>Kramer, M.A. ; van der Maas, N.A.T. ; van Soest, E.M. ; Kemmeren, J.M. ; de Melker, H.E. ; Sturkenboom, M.C.J.M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c367t-3125a7d951a28f7bed7cb025b98c0a48787573e1ff9b2828756bb6304a0bf46b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age</topic><topic>Age Distribution</topic><topic>Aged</topic><topic>Cohort Studies</topic><topic>Databases, Factual</topic><topic>electronic medical records</topic><topic>Female</topic><topic>Humans</topic><topic>Incidence</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis - epidemiology</topic><topic>Netherlands - epidemiology</topic><topic>Original Paper</topic><topic>Retrospective Studies</topic><topic>Sex Distribution</topic><topic>Vaccination</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kramer, M.A.</creatorcontrib><creatorcontrib>van der Maas, N.A.T.</creatorcontrib><creatorcontrib>van Soest, E.M.</creatorcontrib><creatorcontrib>Kemmeren, J.M.</creatorcontrib><creatorcontrib>de Melker, H.E.</creatorcontrib><creatorcontrib>Sturkenboom, M.C.J.M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>Neuroepidemiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kramer, M.A.</au><au>van der Maas, N.A.T.</au><au>van Soest, E.M.</au><au>Kemmeren, J.M.</au><au>de Melker, H.E.</au><au>Sturkenboom, M.C.J.M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Incidence of Multiple Sclerosis in the General Population in the Netherlands, 1996–2008</atitle><jtitle>Neuroepidemiology</jtitle><addtitle>Neuroepidemiology</addtitle><date>2012-09</date><risdate>2012</risdate><volume>39</volume><issue>2</issue><spage>96</spage><epage>102</epage><pages>96-102</pages><issn>0251-5350</issn><eissn>1423-0208</eissn><abstract>Background: We estimated the multiple sclerosis (MS) incidence in the Netherlands for better active monitoring of potential vaccine safety signals. Methods: A retrospective cohort study (1996–2008) was conducted using a population-based general practice research database containing electronic medical records. Additional information was collected to validate incident probable cases. Results: In the source population (648,656 persons), 146 incident probable MS cases were identified. Overall incidence rate was 6.3/100,000 person years (py; 95% CI, 5.2–7.2). In the subgroup in which MS could be fully validated, the incidence increased from 4/100,000 py (95% CI, 3–5) in 1996–2004 to 9/100,000 py in 2007/8 (95% CI, 6–16). This increase was highest among women, but not statistically significantly different by gender. The median lag time between first recorded symptoms and MS diagnosis decreased from 32 months (<1998) to 2 months (>2005). Conclusions: MS is rare in the Netherlands. In recent years, there was a slight increase in the incidence especially among women during the fertile age. This increase coincided with a decrease in lag time between symptoms and diagnosis, both for men and women. This trend should be taken into account in the interpretation of MS cases occurring in a population where new vaccinations will be introduced shortly.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>22814194</pmid><doi>10.1159/000338678</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0251-5350 |
| ispartof | Neuroepidemiology, 2012-09, Vol.39 (2), p.96-102 |
| issn | 0251-5350 1423-0208 |
| language | eng |
| recordid | cdi_karger_primary_338678 |
| source | MEDLINE; Karger Journals; Alma/SFX Local Collection |
| subjects | Adolescent Adult Age Age Distribution Aged Cohort Studies Databases, Factual electronic medical records Female Humans Incidence Male Middle Aged Multiple sclerosis Multiple Sclerosis - epidemiology Netherlands - epidemiology Original Paper Retrospective Studies Sex Distribution Vaccination Vaccines |
| title | Incidence of Multiple Sclerosis in the General Population in the Netherlands, 1996–2008 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T09%3A08%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Incidence%20of%20Multiple%20Sclerosis%20in%20the%20General%20Population%20in%20the%20Netherlands,%201996%E2%80%932008&rft.jtitle=Neuroepidemiology&rft.au=Kramer,%20M.A.&rft.date=2012-09&rft.volume=39&rft.issue=2&rft.spage=96&rft.epage=102&rft.pages=96-102&rft.issn=0251-5350&rft.eissn=1423-0208&rft_id=info:doi/10.1159/000338678&rft_dat=%3Cproquest_karge%3E1093447730%3C/proquest_karge%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1267828202&rft_id=info:pmid/22814194&rfr_iscdi=true |